Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting

Aim: To compare all-cause and acute lymphoblastic leukemia (ALL)-related healthcare resource utilization (HCRU) and costs among patients receiving inotuzumab ozogamicin (InO) and blinatumomab (Blina) for ALL in the first relapsed/refractory (R/R) setting. Patients & methods: We studied retrospecti...

Descrición completa

Detalles Bibliográficos

Principais autores:	Alexander Russell-Smith, Louise Murphy, Amy Nguyen, Cori Blauer-Peterson, Marilou Terpenning, Feng Cao, Shiqiang Li, Tim Bancroft, Noah Webb, Stephanie Dorman, Richa Shah
Formato:	Artigo
Idioma:	Inglês
Publicado:	Becaris Publishing Limited 2023-12-01
Series:	Journal of Comparative Effectiveness Research
Assuntos:	acute lymphoblastic leukemia costs health care resource utilization medications relapse/refractory
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!